Keros Therapeutics Updates on Clinical Trials and Safety

TipRanksJan 10 21:31

BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $33

Futu NewsJan 6 19:34 · Ratings

Keros Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesDec 23, 2024 20:51 · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43

Futu NewsDec 23, 2024 20:33 · Ratings

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

MT NewswiresDec 23, 2024 19:52 · Ratings

Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential

TipRanksDec 23, 2024 19:45 · Ratings